Tempus AI Hits Major Milestone with $1.1 Billion in Contracts
Tempus AI achieves record $1.1 billion in total contract value, partners with 70+ pharmaceutical companies, and reports 31% revenue growth in 2025.
/ 9 items
#AZN↓
Walmart Joins Nasdaq-100 Index; Stock Rises
Walmart stock surges 3.5% in premarket trading as the retail giant prepares to join the Nasdaq-100 index on January 20, 2026, following strong annual growth.
Compugen Secures $90M Deal with AstraZeneca
Compugen monetizes cancer drug royalties to AstraZeneca (AZN) for up to $90 million, extending operations until 2029 while retaining majority future earnings.
GSK Raises 2025 Profit Forecast as HIV and Cancer Drugs Drive Growth
GSK boosts annual profit forecast to 12% growth as specialty medicines outperform. CEO Emma Walmsley's final report shows strong Q3 results despite US vaccine challenges.
Shah Capital Urges Novavax Sale After COVID Vaccine Struggles Continue
Novavax's second-largest shareholder Shah Capital pushes for company sale, citing poor COVID vaccine sales and untapped potential worth $5 billion under larger pharma ownership.
AstraZeneca Secures Tariff Relief by Pledging Deep Drug Discounts and $50 Billion U.S. Investment
AstraZeneca joins Pfizer in a landmark agreement with the Trump administration, promising "most-favored nation" drug prices, direct-to-consumer sales up to 80% off list price, and a massive investment in U.S. manufacturing in exchange for a three-year tariff exemption.